We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

47 hedge funds and large institutions have $21.8M invested in ImmunityBio in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

232% more capital invested

Capital invested by funds: $6.57M → $21.8M (+$15.2M)

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

21% more funds holding

Funds holding: 39 → 47 (+8)

0.36% more ownership

Funds ownership: 5.48% → 5.84% (+0.36%)

0% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 11

70% less call options, than puts

Call options by funds: $94K | Put options by funds: $309K

Holders
47
Holders Change
+8
Holders Change %
+20.51%
% of All Funds
0.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
11
Reduced
11
Closed
6
Calls
$94K
Puts
$309K
Net Calls
-$215K
Net Calls Change
-$175K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$544K
2
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$237K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$226K
4
CS
Credit Suisse
Switzerland
+$215K
5
BCM
Bridgeway Capital Management
Texas
+$185K

Top Sellers

Rank Fund Capital Flow
1
WCM
Wildcat Capital Management
New York
-$600K
2
HKAM
Horizon Kinetics Asset Management
New York
-$250K
3
Millennium Management
Millennium Management
New York
-$186K
4
TRCT
Tower Research Capital (TRC)
New York
-$58K
5
OC
Oppenheimer & Co
New York
-$28.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$6.2M +$66.7K +39,200 +2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$4.07M +$296 +174 +0%
BlackRock
3
BlackRock
New York
$2.58M +$544K +319,902 +89%
Millennium Management
4
Millennium Management
New York
$1.17M -$186K -109,280 -26%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.09M +$46.3K +27,216 +10%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$794K -$25.7K -15,128 -7%
Charles Schwab
7
Charles Schwab
California
$625K +$64.1K +37,660 +30%
JP Morgan Chase
8
JP Morgan Chase
New York
$596K +$52.1K +30,604 +24%
Qube Research & Technologies (QRT)
9
Qube Research & Technologies (QRT)
United Kingdom
$527K +$237K +139,101 New
Susquehanna International Group
10
Susquehanna International Group
Pennsylvania
$504K +$226K +132,930 New
CS
11
Credit Suisse
Switzerland
$480K +$215K +126,609 New
Bank of New York Mellon
12
Bank of New York Mellon
New York
$414K -$2.53K -1,485 -1%
BCM
13
Bridgeway Capital Management
Texas
$412K +$185K +108,700 New
ECM
14
ExodusPoint Capital Management
New York
$349K +$157K +92,153 New
HKAM
15
Horizon Kinetics Asset Management
New York
$314K -$250K -146,976 -64%
Northern Trust
16
Northern Trust
Illinois
$232K +$6.45K +3,793 +7%
OGC
17
One68 Global Capital
New York
$230K +$103K +60,776 New
6CM
18
683 Capital Management
New York
$223K +$100K +58,748 New
Bank of Montreal
19
Bank of Montreal
Ontario, Canada
$115K – – –
Simplex Trading
20
Simplex Trading
Illinois
$72K +$32.4K +19,014 New
LCM
21
Laurion Capital Management
New York
$65K +$29.3K +17,200 New
Creative Planning
22
Creative Planning
Kansas
$63K – – –
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$61K +$1.78K +1,045 +7%
OC
24
Oppenheimer & Co
New York
$59K -$28.9K -17,000 -52%
FAAS
25
First Allied Advisory Services
California
$59K – – –
1
2

IBRX Hedge Fund Activity: Q4 2019 in Review

47 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2019, worth a combined $21.8M — up 232% from $6.57M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IBRX positions and 6 closed out — a net gain of 8 holders — while 11 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $544K. The largest seller was Wildcat Capital Management, exiting entirely with an estimated $600K sold.

  • 47 institutional investors held ImmunityBio (IBRX) as of Q4 2019, up from 39 in Q3 2019.
  • Funds reported $21.8M of ImmunityBio stock for Q4 2019, up 232% quarter-over-quarter.
  • 14 funds opened new ImmunityBio positions in Q4 2019 and 6 closed out, a net change of +8 holders.
  • The largest ImmunityBio buyer in Q4 2019 was BlackRock, an estimated $544K added.
  • The largest ImmunityBio seller in Q4 2019 was Wildcat Capital Management, an estimated $600K sold.

Based on aggregated 13F filings for Q4 2019.